The European Pharmaceutical Industry in a Global Economy: what drives EU exports of pharmaceuticals?. Bruges European Economic Research Papers (BEER) 31/2015. by Blanc, Ludivine
DEPARTMENT OF 
EUROPEAN ECONOMIC STUDIES
The European Pharmaceutical 
Industry in a Global Economy:
what drives EU exports of 
pharmaceuticals ? 
Ludivine Blanc
Bruges European Economic Research Papers 31 / 2015
 About the author: 
Ludivine Blanc holds a Master’s degree in European Economics Studies from the 
College of Europe and Master’s degree in European Studies from the University of 
Maastricht and the Grenoble Institute of Political Studies.  
 
Address for correspondence:  
Ludivine Blanc: ludivine.blanc@coleurope.eu 
 
Acknowledgements:  
This paper is largely based on the Master’s thesis of Ludivine Blanc at the College of 
Europe,  where she studied with a scholarship from Campus France. 
The author is grateful to Prof.  Phedon Nicolaides for comments on a previous draft.  
The usual disclaimer applies. 
  
The European Pharmaceutical Industry in a Global 
Economy: 
what drives EU exports of pharmaceuticals?* 
 
BEER n° 31 
Ludivine Blanc 
 
Abstract  
The pharmaceutical industry is one of the most competitive sectors in the European 
Union. With its substantial investments in research and development, this industry 
represents a key asset for the European economy and a major source of growth and 
employment. However, despite the importance of the pharmaceutical sector for the 
European Union, few researchers have attempted to assess the determinants of the 
EU exports of pharmaceuticals. This paper aims at filling the aforementioned gap by 
examining what drives EU exports of pharmaceuticals. In order to tackle this 
question, this paper has derived hypotheses from the Gravity Model of Trade and 
the relevant academic literature on pharmaceuticals. Based on an econometric 
analysis, the research sheds light on the complex interaction of factors influencing 
the EU exports of pharmaceuticals. The paper finds that the protection of 
intellectual property in the receiving countries, their economic size, the importance 
of their health sector, and the quality of infrastructures constitute major drivers to 
the EU exports of pharmaceuticals. On the contrary, the research shows that 
transports costs as well as tariff barriers and non-tariff barriers tend to hinder the 
EU exports of pharmaceuticals.  
Keywords:  Pharmaceutical industry, Exports, Gravity Model, Intellectual Property 
Rights, Non-tariff barriers, Free Trade Agreements.  
JEL codes:  F14,  C23. 
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1. Introduction  
 
The 2013 Competitiveness report of the European Commission entitled “Towards 
knowledge driven reindustrialisation” highlights some of global issues that the European 
Union needs to address, namely, the decreasing weight of the EU industry in the world, the 
loss of competitive advantages in many sectors and the growing EU-USA productivity gap 
(European Commission, 2013(a), p 13). In light of those challenges, the report argues that 
the European Union should find innovative solutions to maintain its position as a major 
producer of knowledge in key enabling technologies and vital high-tech sectors. Being one 
of the top performing industries of the European Union, the pharmaceutical sector has a 
crucial role to play in fostering EU growth and competitiveness. With its annual output of € 
220 billion and its substantial investment in R&D compared to other manufacturing sectors, 
the EU pharmaceutical industry is a strategic asset to the EU economy (European 
Commission, 2014). According to the 2012 EU Industrial R&D Investment Scoreboard, the 
pharmaceutical and biotechnology sectors represent 17.7% of business R&D expenditures 
in the world (European Commission, 2012(a), p 43). The pharmaceutical industry is also of 
crucial importance for the EU which is the major world trader in medicinal and 
pharmaceutical products. In 2012, the extra-EU-27 exports of pharmaceuticals accounted 
for € 106 353 027 millions (European Commission, Market Access database, 2014).  
However, despite the importance of this sector for Europe, the literature on the EU exports 
of pharmaceuticals is rather scarce. Most of the research on the pharmaceutical industry 
concerns its impact on the health sector (for few examples see Rhee, 2008; Mills, Hanson & 
McPake, 2002) and the respect of competition rules by pharmaceutical companies 
(Roberts, 2009; Danzon & Chao, 2003). Furthermore, the research on the drivers of the EU 
exports of pharmaceuticals is almost non-existent in the academic literature. The aim of 
this paper is therefore to address the aforementioned gap by analysing the main 
determinants of the EU exports of pharmaceuticals using the gravity model of trade. 
Beyond its academic contribution, the ambition of this research is to enhance our 
knowledge of the factors driving the EU exports of pharmaceuticals in order to remain a 
major world exporter in the future.  This research appears all the more necessary in a 
context of economic crisis and slow internal demand where trade is expected to play a 
crucial role in fostering EU growth and competitiveness.  
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Indeed, the European Commission predicts that “the contribution of external demand to 
economic growth is bound to increase in future, as 90 % of global economic growth by 2015 
is expected to be generated outside Europe, a third of it in China alone” (European 
Commission, 2012(b ), p. 4).   
The literature on the gravity model of trade will serve as a theoretical foundation for this 
research. The paper uses a combination of quantitative and qualitative research methods 
to examine the determinants of the EU exports of pharmaceuticals. The econometric 
analysis enables us to test the statistical significance of a wide range of variables on the 
EU exports of pharmaceuticals namely, the protection of intellectual property, the level of 
healthcare expenditure of the partner country, the existence of a Free Trade Agreement, the 
transport costs, the health status and the Gross Domestic Product (GDP) of the receiving 
country.  
The remainder of the paper is organised as follows. The following section offers an 
overview of some of the main barriers for the pharmaceutical industry based on official 
reports. The third section presents the theoretical framework which combines insights from 
the Gravity Model of Trade as well as the relevant literature on the subject. The fourth 
section of this paper provides an econometric analysis of the determinants of the EU 
exports of Pharmaceuticals.  Finally, the fifth section concludes on the main drivers and 
obstacles to the trade of pharmaceuticals.   
 
2. Literature review on the main exports barriers for the pharmaceutical sector 
 
The aim of this part is to provide a qualitative analysis of some of the main barriers related 
to the trade of pharmaceuticals. The findings of this part are based on a review of the 
official reports related to the pharmaceutical industry. 
 
2.1. Tariff barriers 
Since 1947, multilateral negotiations through the World Trade Organization as well as 
bilateral and regional trade agreements have contributed to lower drug tariff. Today, most 
of the OECD members have zero tariffs for pharmaceutical products as a result of the 
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Uruguay round (1986-1994) (Kiriyama: OECD, 2011, p. 43). However, emerging countries 
such as China, India, Russia, MERCOSUR and ASEAN countries still impose high tariff on 
pharmaceutical imports from the European Union (European Commission, 2011(a), p. 9).  
For instance, the report from the European Commission cited above indicates that a tariff of 
10% is applied to EU generics containing penicillin and their derivatives in India (p. 9). These 
high tariffs imposed by some emerging countries are a source of concern for the EU 
pharmaceutical industry as it increases the price of their products overseas and limits the 
access to medicines (interview EFPIA, February 2014). According to the OECD, 66.8% of the 
revenues gained from tariff on pharmaceuticals are earned by the 10 non-OECD members in 
2008 (Kiriyama, op. cit, p. 44). The weighted average tariff in these countries was 7.58% in 
2008 (ibid, p. 44). Table 1 illustrates more in detail the difference of tariff on active 
pharmaceutical ingredients and finished products applied by lower, upper-middle income 
and high income countries.   
 
Table 1: Distribution of tariff rates by country groups for active pharmaceutical ingredients 
and finished products containing other antibiotics. 
 a) Active pharmaceutical ingredients containing other antibiotics (300320)  
Tariffs rate 
(%) 
Number of 
countries  
(n= 140) 
Percentage 
of all 
countries 
Low-income 
countries 
Lower-
middle-
income 
countries 
Upper-
middle-
income-
countries 
High-income 
countries 
0 70 50% 22 18 13 17 
0-5 28 20% 9 11 6 2 
5,0-10 29 21% 8 9 10 2 
10,1-20 10 7% 3 4 3 0 
> 20 3 2% 1 2 0 0 
 * MEAN - 4,46 %; MEDIAN - 0,50 %   
 b) Finished products containing other antibiotics (300420)  
Tariffs rate 
(%) 
Number of 
countries  
(n= 148 ) 
Percentage 
of all 
countries 
Low-income 
countries 
Lower-
middle-
income 
countries 
Upper-
middle-
income-
countries 
High-income 
countries 
0 64 43% 21 14 12 17 
0-5 35 24% 11 14 7 3 
5,1-10 34 23% 10 10 10 4 
10,1-20 13 9% 3 7 3 0 
> 20 2 1% 1 1 0 0 
* MEAN - 5,14  %; MEDIAN - 3, 5 %  
 
Source: Olcay & Laing (2005, p. 27) 
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The report conducted that Müge Olcay and Richard Laing (2005, p. 38) shows that even 
though the revenues generated from the levies on medicines are quite small, these tariffs 
may limit the access of the poor and the sickest to affordable medicines.  
2.2.  Non-tariff barriers  
Due to their impact on the health sector, pharmaceutical products are highly regulated. 
Although most of the regulations and standards are justified, they may significantly affect 
the trade of pharmaceuticals. It is therefore essential to ensure that the measures are 
strictly necessary and that do not represent discriminatory or disproportionate regulations 
or standards. Non-tariff barriers (NTBs) are one of the most important sources of concern 
for the pharmaceutical sector.  These NTBs can take several forms ranging from 
registration, certification, or government policies concerning the price and the 
reimbursement of medications (European Commission, 2011(a), p. 10).  Registration 
barriers can represent a serious obstacle to the trade of pharmaceuticals. Indeed, 
additionally to the standards set by European Medicine Agency, EU producers have to 
comply with many requirements to obtain an authorization to export their products (ibid, p. 
11).  These certificates can differ from one country to another which increases the 
administrative burden on pharmaceutical companies. In emerging economies such as 
China, India, Russia, and Brazil, the EU has to comply with different requirements and 
market authorizations which are often very long to obtain (ibid, p. 11).  Pharmaceutical 
companies are also affected by non-tariff measures (NTM) in developed countries such as 
Japan and the United States. For instance, the regulatory differences between the United 
States and Europe induce an additional cost of 9.5% for EU exporters (Berden, François, 
Thelle, Wymerga, Tamminen, 2009, p. 30). Moreover, non-tariff barriers in Japan are 
estimated to increase the cost of EU pharmaceutical exports by 22 percent (Sunesen, 
Francois and Thelle, 2009, p. 10).  
This is why, in addition to the discussions launched at multilateral level, the European Union 
has started many bilateral negotiations with countries to eliminate non-tariff barriers with 
its key partners. According to a recent report, a reduction of 2% of non-tariff barriers in 
Japan could boost EU exports of pharmaceuticals by 60% (Sunesen, Francois & Thelle, 
2009, p. 10). Moreover, the annual income gain from an EU-US Transatlantic Trade and 
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Investment Partnership (TTIP) for the EU chemical cosmetic & pharmaceutical sector is 
expected to vary between $ 7.1 and 9.2 billion (Koen et al, 2007, p. 26).   
2.3. The protection of Intellectual Property Rights  
Since the Pharmaceutical industry is very research intensive, the protection of Intellectual 
Property is crucial to preserve the competitiveness of this industry. Indeed, the lack of 
enforcement of IPR creates disincentives for innovation and prevents pharmaceutical 
companies to recoup their investments in R&D. A study conducted by Lanjouw in 2005 also 
confirms that stronger patent protection will encourage companies to launch more rapidly 
new drugs in the market (cited in Kiriyama: OECD, p 52). Counterfeiting medicines1 and 
Piracy are also considered as one of the most important issue by the EU pharmaceutical 
industry. Indeed, counterfeit medicines create a disincentive for originators companies to 
invest in R&D to develop new drugs and threaten the competitiveness of this industry. 
According to a report from European Alliance for Access to safe medicines, the volume of 
counterfeiting seized in Europe has considerably increased in the latest years. For instance, 
in 2006, 2.7 million of counterfeit products were found which represent more than 8 times 
the volume discovered in 2004 (p. 10).  
Three countries can be considered as problematic regarding the respect of Intellectual 
Property Rights namely China, India and Canada (European Commission, 2011, p.15). In 
China, concerns related to the protection of Intellectual Property Rights do not arise from 
the lack of regulation on IPR but from the inadequate enforcement of the regulation on IPR 
which facilitates the production and selling of counterfeiting. The cost of counterfeiting 
drugs for pharmaceutical groups in China represents 10% to 25% of their annual sales (ibid, 
p. 94).  
The EU pharmaceutical industry is also concerned with the insufficient enforcement of IP 
regulation in India (UK Intellectual Property Office, 2013, p. 9). Indeed, once pharmaceutical 
companies have applied for a patent, they often have to wait two years for the patent to be 
examined and approved (Kiriyama, 2011, p. 53). Moreover, the Indian government and the 
                                                      
 
1 According to the European Alliance for Access to safe medicines (2008): “A medicine is counterfeit 
when it is deliberately and fraudulently mislabelled with respect to its identity, history and/or source” 
(p. 8). 
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Supreme Court apply a restricted interpretation of Intellectual Property Rights to facilitate 
the replacement of more expensive life-saving medicines by cheaper generic drug. For 
instance, in 2013, the Supreme Court in India has rejected a plea from Novartis to patent the 
cancer treatment drug “Glivec”. However, this situation can hamper the competitiveness of 
drug manufacturers who have to bear the high costs of R&D to develop new drugs but may 
not be able to fully recoup their investments due to the lack of Intellectual Property 
Protection.  
Compared to many developed countries, Canada is lagging behind in the protection of 
Intellectual Property Rights (European Commission, 2013(c), p. 1). Indeed, the Canadian law 
on data protection only applies to a small subset of new medicines. Thus, only drug 
ingredients that are contained within a medication for the first time will receive benefit from 
data protection (Kierans, Wagner, Thill-Tayara, 2011, p. 3). This means that a medicine 
combining several drug ingredients will not be subject to Intellectual Property Protection 
unless it contains at least one innovative component (ibid). The weak protection of 
intellectual property rights in Canada compared to other developed countries is an 
important source of concern for the EU pharmaceutical industry. The official reports show 
that the protection of intellectual property rights represents an major challenge for the 
European pharmaceutical industry in the different countries mentioned above. This is why it 
would be interesting to analyze in this paper how the level of intellectual property rights in 
different countries affects the EU exports of pharmaceuticals.  
 
3. Theoretical framework  
3.1. The gravity model of trade  
The gravity model of Trade serves as a theoretical framework for this paper. This model has 
become more and more popular in international trade literature. This approach provides a 
powerful tool to analyse trade flows between countries and the trade impact of different 
policies. Moreover, according to Learner and Levinsohn (1995), the Gravity model of Trade 
has delivered “some of the clearest and most robust findings in empirical economics” (cited 
in Shepherd, 2013, p. 13).  
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The Gravity Model departs from Newton’ Law of Gravity which states that the gravity 
between two objects is positively correlated with their masses and inversely related to the 
distance between them. This is translated into the following equation:  
𝐹𝑖𝑗 = 𝐺 ∗
𝑀𝑖𝑀𝑗
𝐷²𝑖𝑗
              (1)    
Where F denotes the gravitational force between two particles and Mi and Mj represent the 
masses of these two objects. D expresses the distance between the two objects while G is 
a gravitational constant. In order to perform a regression analysis, Gravity models are 
expressed in natural logarithms (‘‘ln’’). Thus, the first equation (1) is transformed into the 
following linear equation (2) (Renert, 2008, p. 568). 
ln 𝐺𝐹𝑖𝑗 = ln 𝑀𝑖 + ln 𝑀𝑗 − ln 𝐷𝑖𝑗          (2) 
 
International Trade theorists depart from this equation and replace the gravitational forces 
by the trade flows or the exports from country i to country j (Eij in the third equation). While 
the variable Distance remains the same, Mi and Mj are measured by the Gross Domestic 
Product (GDP) of the countries i and j. b1 and b2 are expected to be positive whereas the 
sign of b3 should be generally negative.   
ln 𝐸𝑖𝑗 = 𝛼 + 𝑏1 𝑙𝑛𝐺𝐷𝑃𝑖 + 𝑏2 𝑙𝑛𝐺𝐷𝑃𝑗 + 𝑏3 𝑙𝑛𝐷𝑖𝑗   (3) 
 
Tinbergen (1962) and Anderson (1979) were the first scholars to apply the Newton’ Law of 
Gravity to analyse Trade flows between countries. Both authors consider transport costs 
measured by the geographical distance between two countries as a crucial factor to explain 
the intensity of trade volume between countries. The literature on the Gravity Model of 
Trade uses alternatively the variables GDP, GDP per capita or GDP and population to 
measure the masses of the economies of country i and j. Most of the empirical studies in 
this field show that these variables have a strong positive impact on the trade flows 
between two countries (for few examples, see Khan, Hag & Khan, 2013; Eita, 2008; Nguyen, 
B. X. 2010).  Scholars using the Gravity Model of Trade have also looked at the potential of 
Free Trade Agreements in fostering Trade relations between countries. For instance, a 
study conducted by Baier and Bergstrang (2001) shows that the reductions in tariff rate and 
trade liberalisation have had a positive impact on the increase in world trade.  
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3.2. Literature review on the Gravity model of trade  
As mentioned previously, the research about the determinants of pharmaceutical products 
is recent and remains quite scarce. Only three studies have tried to evaluate the 
determinants of pharmaceutical trade using the gravity model of trade, two of them 
concern Sweden and the other one relates to the USA trade of pharmaceuticals towards 
emerging countries.  
In his MA thesis, Per Adolfsson used a gravity model of trade to evaluate the impact of 
several factors on the Swedish exports of pharmaceuticals based on the method of fixed 
panel data (Adolfsson, 2007). The author ran three regressions with different dependant 
variables for each of them.  In the first regression, Per Adolfsson measures the exports of 
pharmaceuticals from country i to country j in Swedish krona (SEK) at time t. In the second 
model, the author considers the exports of pharmaceuticals in kilogrammes from country i 
to country j. In the third regression, the dependent variable concerns the exports of 
pharmaceuticals from country i to country j in SEK per unit at time t. The independent 
variables used in the three regressions are the following: the logarithm of the distance 
between the two countries in kilometres, the GDP per capita in dollars for country j at time t, 
the area of the country j, the population of country j at time t and some dummy variables 
concerning the religion, the language and the access to the ocean of the receiving country. 
However, one of the limits of this research is that the author is using a dependant variable 
which is measured in Swedish krona (SEK) whereas some of the independent variables 
such as the GDP and the GDP per capita of the receiving countries are measured in dollars. 
Moreover, one may also question the choice of the author to measure the exports of 
pharmaceuticals in kilos as the range of pharmaceutical products exported is very broad. 
Per Adolfsson’s main conclusion is that the regressors “GDP per capita” have a significant 
positive impact on the exports of pharmaceuticals measured in SEK, kilograms and 
kilograms per unit (at 5% level). He shows that landlocked and remote countries are less 
likely to import goods from Sweden. The result of this econometric analysis also reveals 
that Sweden exports more pharmaceuticals towards countries that share the same religion.  
The research conducted by Mats Wilkman also aims at evaluating the determinants of 
Swedish exports of pharmaceuticals (Wilkman, 2012). The author relies on a very similar 
research design than Per Adolfsson to explain the Swedish trade of pharmaceuticals.  
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The author ran two regressions using two different dependant variables: the exports of 
pharmaceuticals in SEK and the exports of pharmaceuticals in kilograms per unit. Mats 
Wilkman tested the same independent variables as Per Adolfsson in his research and 
added one regressor concerning the exchange rate between the Swedish krona and the 
dollars. However, the author does not include any explanatory factors related to the health 
sector or the protection of intellectual property rights to explain the exports of 
pharmaceuticals from Sweden to other countries.  
At the end of his dissertation, Mats Wilkman concludes that the Swedish exports of 
pharmaceuticals are determined by the same factors as most other goods (p. 26). Indeed, 
this author shows that Sweden will export more pharmaceutical products to countries that 
have a higher GDP, GDP per capita and that share the same language. On the contrary, 
pharmaceutical exports are negatively related to the distance between two countries and 
changes in the exchange rate.  
In her paper entitled “Determinants of the United States’ trade of pharmaceuticals”, Anne 
Boring (2010) uses several econometric models including a panel data with fixed effects to 
determine the most significant factors influencing the USA exports of pharmaceuticals 
towards emerging countries. One of the major innovations of Anne Boring’ paper is to 
include two dummy variables in the gravity equation to measure the effect of Intellectual 
Property Rights (IPR) on the USA exports towards emerging countries. The first one 
correspond to the binary variable “Free Trade Agreement” (FTA) which takes the value one 
when the country has signed an agreement with the United States. The variable FTA was 
expected to capture the effect of a strong IPR protection (p.8). Anne Boring also created a 
dummy variable called “TRIPS” which takes the value one when the country has 
implemented the agreement on Trade-Related Aspects of Intellectual Property Rights set by 
the World Trade Organization. When no information was available about the 
implementation of the TRIPS agreements, the author used the deadlines set in those 
documents (ibid, p. 8). However, one of the limits of this measurement is that the official 
date of the implementation of the TRIPS agreement might not necessarily reflect the real 
level of IPR in the country. Indeed, although some countries have adopted a legislation on 
Intellectual Property Rights in conformity with the TRIPS agreement, the regulation is not 
always properly enforced on the ground. Moreover, the variable Free Trade Agreement may 
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not only capture the impact of Intellectual Property Protection but also the effects resulting 
from the elimination of other trade barriers between the USA and its partners.  
The result of Anne Boring’s analysis shows that the effect of Intellectual Property Rights is 
statistically insignificant to explain the USA exports of pharmaceuticals. Indeed, the 
variable “TRIPS” is almost always insignificant except in the reduced Ordinary Least Square 
(OLS) regression where the authors takes into account three basic elements of the gravity 
equation and the variable “Free Trade Agreement”.  
The last variable mentioned is insignificant in all the regressions performed. Additionally, 
Anne Boring found that the following factors had a statistically significant positive impact 
on the USA exports of pharmaceuticals: the natural logarithm of the GDP of the partner 
country j, the existence of a common language between the two countries, the presence of 
a major container port in the receiving country, out-of-pocket expenditure on health in the 
partner country and the adhesion of the receiving country to the “President's Emergency 
Plan for AIDS Relief” launched by George Bush in 2003. On the contrary, the natural 
logarithm of the distance between the countries (statistically significant at 1% level) and 
the incidence of tuberculosis per 100 000 people (statistically significant at 10% level) have 
a negative impact on the USA exports of pharmaceuticals towards emerging countries.  
 
4. Methodology  
The aim of this research is to test the impact of several variables on the extra EU-25 exports 
of pharmaceutical products. This research is based on a list of 62 countries from different 
regional groups over a period of 8 years (2004-2011). The diversity of the countries selected 
follows a recommendation done by Jeffrey A. Frankel (1997, p. 55) in his book on “Regional 
Trading Blocs in the World Economic System” in which he argues that “limiting the analysis 
to industrialized countries is no longer convincing, even if they once were”. The 62 countries 
used in this paper account for 90% of extra-EU exports of pharmaceuticals (see list in 
appendix 1). The panel data start in 2004,  which corresponds to the enlargement of the 
European Union to eight Central and Eastern European countries, Cyprus and Malta.  
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The period selected (2004-2011) shows the factors influencing the EU-25 exports of 
pharmaceuticals before and after the beginning of the EU crisis which started in 2008.  
 
Table 2: variables included in the econometric model 
Type of 
variable 
 
 
Description of the variable 
Expected effect 
on dependent 
variable 
 
Source 
Dependent 
variable (y1) 
Exports of pharmaceuticals 
in dollars from the EU to the 
country j 
-- United Nation Comtrade 
database extracted via the World 
Integrated Trade Solution (WITS)   
Independent 
variable (x2) 
Natural logarithm of the GDP 
of the partner country in 
current dollars  
Positive World Bank database.  
Independent 
variable (x3) 
Natural logarithm of the 
distance in kilometers  
Negative Website : 
http://www.distance2villes.com/ 
 
Independent 
variable (x4) 
Health expenditure as 
percentage of GDP 
Positive World Health Organisation 
database 
Independent 
variable (x5) 
Presence of a major port 
container in the receiving 
country (1) or not (0) 
Positive World Shipping Association’s 
website  
Independent 
variable (x6) 
The country is landlocked 
(1) or has an access to the 
Ocean (0) 
Negative Mayer & Zignago (2011), Geodist. 
Centres d’Etudes Prospectives 
Internationales (CEPII) 
Independent 
variable (x7) 
Existence of a Free Trade 
Agreement between  EU and 
the country j (1) or not (0)   
Positive European Commission, website 
DG Enterprise and Industry.  
Independent 
variable (x8) 
The number of people 
affected by tuberculosis in 
the country (out of 100 000 
inhabitants).  
Negative World Health Organisation 
Database  
Independent 
variable (x9) 
 
[latest 
regression] 
The protection of Intellectual 
Property Rights in different 
countries. The index is  
ranked between 0 and 10 
Positive Database created from the 2007, 
2008, 2009, 2010, and 2011 
Reports by the Property Rights 
Alliances on Intellectual Property 
Rights Index.  
 
The variables selected stem from the classical model of Gravity and from the review of the 
literature on the main determinants of pharmaceutical exports. The selection of the 
variables has been adapted to the case of the EU exports of pharmaceuticals. The 
dependant variable is the natural logarithm of the EU exports of pharmaceuticals towards 
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the partner country expressed in current USA dollars. Following the recommendation of 
several scholars including James E. Anderson and Eric van Wincoop (2003, p. 170) as well 
as Marc Bacchetta et al (2012, p. 111), this paper uses the values of exports in nominal 
value rather than in real terms.  
The research attempts to evaluate the explanatory power of seven independent variables 
on the EU exports of pharmaceuticals.  
 The first variable corresponds to the natural logarithm of the Gross Domestic Product 
(GDP) of the partner country (country j) in current dollars. The GDP is expressed in 
nominal terms rather than in real terms. Indeed, according to a recent report of the 
World Trade Organisation (2012, p. 111): “Gravity is an expenditure function allocating 
nominal GDP into nominal imports; therefore inappropriate deflation probably creates 
biases via spurious correlations”. The GDP of the partner country measuring the 
economic size of the receiving country’s market, it is expected to have a positive 
effect on the dependent variable.  
 The second independent variable is the natural logarithm of the distance between 
Munich and the biggest cities in the partner country measured in kilometers. Munich 
has been selected as it corresponds to one of the most important places in terms of 
pharmaceutical production within the European Union (Mandry & Mac Dougall, 2011, 
p. 4).  The variable distance is used as a proxy for transportation costs. It is expected 
to have a negative influence on the dependent variable. Indeed, it is expected that the 
European Union should trade more with its neighboring countries.  
 The third variable is the health expenditure of country j as a percentage of GDP.  This 
is a proxy for the size of the receiving country’s health care market and should 
therefore have a positive effect on the dependent variable (Boring, 2010, p. 14).   
 The fourth independent variable is a binary variable which measures whether the 
country is landlocked or has access to the sea or the ocean. Landlockedness is 
expected to have a negative influence on the exports of pharmaceuticals as it often 
implies higher transport costs (Raballand, 2002).  
 The fifth explanatory variable is a dummy variable which takes the value 1 when the 
country possesses a major Port container and 0 when it does not.  The data comes 
from the World shipping Council which publishes a list of the top 50 world containers. 
This dummy variable is used as a proxy for infrastructure quality (Boring, p. 8). 
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Therefore, the existence of a major Port container in the country j is expected to have 
a positive influence on its imports of pharmaceutical products from the EU. The 
fourth and fifth variables are complementary as they measure the impact of the 
geographical location and transport infrastructure quality on the exports of 
infrastructure.  
We decide to include both variables as the different tests performed to check for an 
eventual problem of collinearity were rejected.  Indeed, the Pearson correlation 
coefficient is smaller than 0.21 which can be interpreted as a sign of weak correlation 
between the variables according to Cohen (cited by Hemphill, 2003). The calculation 
of the Variance Inflation Factor (VIF) is also used to detect an eventual problem of 
multicollinearity2. To that end, we regressed the variable “Landlocked” on “Port 
Container” and obtained an R² of 0.0438. Based on that, we calculated the VIF which 
is equal to 1.045. As this number is largely inferior to 10, we can conclude that the 
two variables are not collinear.  
 
Table 3: Pearson correlation coefficient. 
 Portcontainer Landlocked 
Portcontainer 1.0000  
Landlocked -0.2094 1.0000 
 
 The sixth independent variable corresponds to the existence of a Free Trade 
Agreement (FTA) between the EU and the receiving country. In general, those 
agreements contain provisions aiming at abolishing tariff and reducing non-tariff 
barriers on pharmaceutical products. Therefore, Free Trade Agreements are expected 
to boost the EU exports of pharmaceutical products overseas.   
Some authors have pointed out that the inclusion of the variable “Free Trade 
agreements” is likely to introduce endogeneity issues in the gravity model in the form 
of “reverse causality” (Baier, S. L. Bergstrand, J. H., 2003).  It means that, in some 
cases, Free Trade Agreements might not only be a determinant of exports but also a 
consequence of these exports. In other terms, major trade partners with similar GDP 
and which are closed to each other would tend to sign more Free Trade Agreements. 
                                                      
 
2 The VIF equal or superior to 10 indicates a problem of multicollinearity. 
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One of the solutions sometimes proposed to solve this problem is to use Non-Tariff 
Barriers as a measure of trade costs. This can be done by assessing the amount of 
technical regulations and standards that may affect the trade flows between some 
countries. However, Anderson and Wincoop (2001) argue that these two types of non-
tariff barriers can be neglected as they do not affect significantly the results. 
Furthermore, Novy and Chen (2011) also point out that measuring the presence or the 
amount of standards also raises some problems of endogeneity bias. As these 
authors underline it (p. 407):  “Explicit measures to capture the presence or the amount 
of standards and regulations by using dummy or count variables, frequency or coverage 
ratios but their stringency remains hard to evaluate. Implicit measures suffer from similar 
problems. It should be added that the possible endogeneity of standards and regulations-
however measured-in explaining trade flows is another concern”.  Although we are aware 
of the potential problems of endogeneity related to the measurements of trade costs, 
we still decided to include this variable “Free Trade Agreement” in the Gravity model 
of trade for several reasons. First of all, the results of the regression are robust and do 
not vary significantly with the introduction of the variable FTA. Secondly, as they are 
no other alternative measures of trade facilitation which would ensure better results, 
the variable Free Trade Agreement has been included in the model.  
 The variable “Tuberculosis” represents the number of people affected by tuberculosis 
in the country out of 100 000 inhabitants. It is as a proxy for the country’s health 
status which is mainly used as a control variable. We expect this explanatory variable 
to have a negative impact on the dependent variable. Indeed, the EU should export 
less pharmaceutical products to countries with low health status (Boring, 2010, p. 9). 
 The last regression of this empirical chapter also aims at evaluating the effect of the 
respect of Intellectual Property Rights on the EU exports of pharmaceuticals. In order 
to measure the impact of this variable on the exports of pharmaceuticals, a database 
has been built by using the index on “Intellectual Property Rights” developed in four 
annual reports conducted by the Property Right Alliance (from 2007 to 2011). 
 The Intellectual Property Rights varies between 1 and 10 and comprises four 
dimensions: the protection of Intellectual Property rights, the patent strength, the 
copyright piracy and trademark protection (Property Right Alliance, 2007, 2008, 2009, 
2010, and 2011). The higher the index, the stronger the level of Intellectual Property 
Rights in the country. In order to calculate the IPR index, four main sources were used 
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by the Property Rights Alliance: the World Economic Forum’s Global Competitiveness 
Index on Intellectual Property Rights, the Ginatre-Park Index of Patent Rights, the US 
Trade Representatives Watch List Report conducted by the International Intellectual 
Property Alliance, and the International Trademark Association’ Report. In each case, 
the data was rescaled from 0 to 10.  
A weighted average of each of those four elements was calculated to obtain the 
ranking of the countries for the index of Intellectual Property Rights.  
Classical gravity models have generally used cross-section data to evaluate trade relations 
between several countries for a given year.  However, panel data analyses enable us to 
observe the influence of some independent variables on the dependant variable across time 
and provide more useful information than simple cross data 
Indeed, by incorporating both cross-sectional and time series dimensions, panel data 
deliver more accurate inference of the variables tested and control for the effect of missing 
or unobserved variables. In light of those advantages, this paper will rely on the method of 
static panel data3.  Using our dataset, we estimate the following gravity equation: 
𝑙𝑛𝑒𝑥𝑝𝑜𝑟𝑡ijt   = β1𝑙𝑛𝐺𝐷𝑃𝑗 + β2 𝑙𝑛𝑑𝑖𝑠𝑡𝑖𝑗  +  𝛽3 ℎ𝑒𝑎𝑙𝑡ℎ𝑠𝑝𝑒𝑛𝑑𝑖𝑛𝑔𝑗𝑡 + β4 𝑙𝑎𝑛𝑑𝑙𝑜𝑐𝑘𝑒𝑑𝑗 +
 β5 𝐹𝑇𝐴𝑖𝑗𝑡 +  β6 𝑇𝑢𝑏𝑒𝑟𝑐𝑢𝑙𝑜𝑠𝑖𝑠𝑗𝑡 +  β7 𝑃𝑜𝑟𝑡𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑒𝑟𝑗 +  αn 𝐶𝑜𝑢𝑛𝑡𝑟𝑦𝑛 +  𝜔𝑛 𝑌𝑒𝑎𝑟𝑛 + Uijt  
Where   
lnexportijt= natural logarithm of the EU exports of pharmaceuticals (country i) towards the 
partner country (country j) expressed in current dollars,  
lnGDPj  = natural logarithm of the GDP of country j in current dollars, 
lndistij = natural logarithm of the distance between country i and country j in kilometers,  
healthspendingj = health expenditure of country j as percentage of its GDP,  
landlockedj= indicates whether the country j is landlocked (1) or has an access to the sea (0), 
FTAij = shows the existence of a Free Trade Agreement between country i and j (1) or not (0),   
Tuberculosisj = number of people affected by tuberculosis in the country j out of 100 000 
inhabitants 
                                                      
 
3 The impact of Intellectual Property Rights on EU exports of Pharmaceuticals will be analyzed by 
conducting an Ordinary Least Square Regression. This is due to the fact that the data on IPR is 
available only from 2007 to 2011.  
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Portcontainerj=indicates the existence of a major port container (1) in the receiving 
country.  
Countryn = dummy variable for the countries included in the model4.  
 Yearn= dummy variable for the years contained in the model
5.  
Uij = error term, 
 t = time period 
Βs = parameters.  
αn = coefficients corresponding to the binary regressors country  
𝜔𝑛 = coefficients for the binary time regressors
6  
We expect the signs of β1, β3, β5, β7 to be positive while β2, β4, β6 should be negative.  
5. Econometric analysis 
5.1. First estimation of the model  
Table 4: Result of the first regression 
Variables Model 1  
ln GDP (dollars) 0.620***      (0.00) 
Free Trade Agreement 0.0880           (0.12) 
Ln distance (kms) -0.320          (0.13) 
Tuberculosis -0.000126      (0.82) 
Landlocked -1.086*       (0.04) 
Health spending 0.0609***      (0.00) 
Port container 0.943           (0.07)   
Constant 5.301** (0.01) 
     
Observations 496  
P-values in parentheses: * p<0.05, ** p<0.01, *** p<0.001 
 
                                                      
 
4 In order not to fall into the dummy trap, we included n-1 countries in the model (that is to say 61 
countries).  
5 To avoid the dummy trap, we exclude the year 2004 of our model. 
6As we are dealing with binary variables, we have t-1 time periods in the equation.  
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The first model was estimated by using the method of panel data with fixed and time 
effects. Subsequently, we regressed the logarithm of the EU exports of pharmaceuticals  on 
the logarithm of the GDP of country j, the logarithm of the distance and the variables 
tuberculosis, healthspending, landlocked, FTA, Portcontainer, i.years7 and i.country8.   
After running this regression, the F-test was carried out to evaluate the joint nullity of all the 
explanatory variables of the model. The test led to a strong rejection of the null hypothesis 
indicating that the fixed effects are highly significant at 1% level. The command testparm 
was also used to verify whether it was necessary to include the binary variables “Countryn” 
and “ Yearn” in our analysis. Both tests led to a strong rejection of the null hypothesis which 
indicates that the two aforementioned variables were statistically jointly significant. The 
other explanatory factors which were found to be statistically significant at 5% level were 
the variable “healthspending”, the logarithm of the GDP of the receiving country and the 
binary variable “landlocked”.  
The variable “Port container” is statistically significant at 10% level. However, the 
explanatory factors “Free Trade Agreement”, “ln distance” and “Tuberculosis” are not 
statistically different from zero even at a 10% level.  
Table 5: Results of the Breusch-Pagan and Ramsey reset test 
Results of the Ramsey RESET test 
Ho: model has no omitted variables 
F(3, 419) =      5.00 
Prob > F =      0.0020 
 
Breusch-Pagan / Cook-Weisberg test for heteroskedasticity 
Ho: Constant variance 
chi2(1)      =    15.48 
Prob > chi2  =   0.0001 
 
Several misspecification tests were also carried out to control for functional form 
misspecification and heteroskedasticity. Given the size of the sample (62 countries over 8 
years), one can assume that the variables are normally distributed.  
                                                      
 
7 i.years is a dummy variable created for each year.  
8 i.country is a dummy variable created for each partner country j.   
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However, the result of the Breusch-Pagan test led to a strong rejection of the assumption of 
homoscedasticity at 1% level (Table 3). The Ramsey RESET test also led to a rejection of 
the null hypothesis at 5% level indicating a problem of functional form misspecification 
(Table 4). This problem can occur when the regression is nonlinear in the parameters.   
 
5.2. Redefinition of the model  
In light of the results of the Ramsey Reset test, we tried to determine which independent 
variables could have a non-linear relation with the dependent variable. First of all, we draw a 
scatterplot between the natural logarithm of the GDP of the receiving country in current 
dollars and the natural logarithm of the EU exports of pharmaceuticals in current dollars. 
The following scatterplot (Graph 1) shows that the relation between these two variables is 
quadratic rather than linear.   
 
Graph 1: Relation between the natural logarithm of the GDP of the country j and the natural 
logarithm of the EU exports of pharmaceuticals in current dollars. 
 
Graph 2 also reveals that the relation between the natural logarithm of the distance in 
kilometers and the natural logarithm of the EU exports of pharmaceuticals in current dollars 
is not linear.  
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Graph 2: Relation between the natural logarithm of the distance in kilometers and the 
natural logarithm of the exports in current dollars. 
 
In light of those results, we therefore introduced two new variables in the model namely the 
square of the natural logarithm of distance in kilometers (ln distance²) and the square of 
the natural logarithm of GDP in current dollars (ln GDP²) in order to avoid the problem of 
functional form misspecification. Moreover, following the result of the Breusch-Pagan test, 
we robustified the regression against heteroskedasticity.  
Therefore, the model is now redefined as follows: 
𝑙𝑛𝑒𝑥𝑝𝑜𝑟𝑡ijt   = β1𝑙𝑛𝐺𝐷𝑃𝑗𝑡 + β2(𝑙𝑛𝐺𝐷𝑃)𝑗𝑡
2 + β3 𝑙𝑛𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒𝑖𝑗 + β3 (𝑙𝑛𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒)𝑖𝑗
2  +
 𝛽3 ℎ𝑒𝑎𝑙𝑡ℎ𝑠𝑝𝑒𝑛𝑑𝑖𝑛𝑔𝑗𝑡 + β4 𝑙𝑎𝑛𝑑𝑙𝑜𝑐𝑘𝑒𝑑𝑗 + β5 𝐹𝑇𝐴𝑖𝑗𝑡 + β6 𝑇𝑢𝑏𝑒𝑟𝑐𝑢𝑙𝑜𝑠𝑖𝑠𝑗𝑡 +
 β7 𝑃𝑜𝑟𝑡𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑒𝑟𝑗 + αn 𝐶𝑜𝑢𝑛𝑡𝑟𝑦𝑛 +  𝜔𝑛 𝑌𝑒𝑎𝑟𝑛 + Uijt  
 
Table 6 presents the result of this regression obtained in STATA9.  The results of this 
regression are quite different from the former model. Indeed, all the explanatory variables of 
this model are statistically significant at 5% level except the variables “tuberculosis” and 
“landlocked”. The Ramset RESET test fails to reject the null hypothesis at 5% level. Since 
this model does not suffer from functional form misspecification, this regression should be 
preferred to the previous one on statistically ground. 
                                                      
 
9 The table only displays the coefficient of the variables of interest in our model.   
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Table 6: Results of the second regression 
Variables Model 2  
ln GDP (dollars) -1.129*   (0.03)    
ln GDP² (dollars) 0.0344*** (0.00)    
Free Trade Agreement 0.122*   (0.04)    
Ln distance (kms) -12.42*** (0.00)    
ln distance² (kms) 0.711*** (0.00)   
Tuberculosis -0.00104    (0.20)    
Landlocked 0.526    (0.31)   
Health spending 0.0510*** (0.00)    
Port container 2.812*** (0.00)    
 
Constant 77.12*** (0.00)    
Observations 496  
P-values in parentheses: * p<0.05, ** p<0.01, *** p<0.001 
Table 7: Result of the Ramsey test 
 
Ho: model has no omitted variables 
F(3, 417) =      0.87 
Prob > F =      0.4577 
 
The coefficient of the variables “FTA”, “Health spending” and “Portcontainer” have the 
expected signs.  Indeed, the existence of a Free Trade Agreement is expected to increase 
EU exports by 12.2% holding other factors constant. Moreover, a one percent point increase 
in health expenditure (as a percentage of GDP) will increase the exports of pharmaceuticals 
in dollars by 5.1%. If a country possesses a major Port container, it is expected to import 
281% more pharmaceutical products from the European Union than if it doesn’t.  
 
In order to better interpret the sign of the coefficients of the variables “ln distance” and “ln 
GDP”, we used the command margin in STATA. This enables us to obtain the partial effect 
of the logarithm of distance and the logarithm of the GDP of the partner country on the 
dependent variable at its mean value. Indeed, the function margin calculates the derivative 
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of the natural logarithm of the EU exports of pharmaceuticals in current dollars with respect 
to the variable “ln GDP” at its mean value. Table 8 displays the result obtained in STATA.  
It shows that the variables “ln GDP” and “ln distance” are statistically significant at 1% level. 
A 1% increase in the GDP of the receiving country is expected to result in a 0.62% increase 
in the EU exports of pharmaceuticals. A 1% in the distance between the EU and the country 
j measured in kilometers is expected to result in a decrease of 0.37% in the EU exports of 
pharmaceuticals towards this state.  
 
Table 8: Partial effect of “ln GDP” and “lndist” on the dependent variable 
 
 Variables dy/dx P>z 
Ln GDP (dollars) .6194133 0.000 
Ln distance (kms) -.3683497 0.001 
 
5.3. Regression with clustered data  
We now consider the possibility that the observations for each country over several years 
are not independent but correlated. In order to control for this problem, we use the cluster 
option on country. Table 9 displays the main results of this model.  
 
Table 9: results of the third regression 
Variables Model 3  
ln GDP (dollars) -1.129    (0.21) 
ln GDP² (dollars) 0.0344    (0.06)    
Free Trade Agreement 0.122    (0.10)    
Ln distance (kms) -12.42*** (0.00)    
ln distance² (kms) 0.711*** (0.00)   
Tuberculosis -0.00104    (0.46)    
Landlocked 0.526    (0.40)    
Health spending 0.0510*   (0.01)    
Port container 2.812*** (0.00)  
Constant     77.12***               (0.00)   
Observations 496  
P-values in parentheses: * p<0.05, ** p<0.01, *** p<0.001 
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The result of this regression is different from the previous one. Indeed, the variables “ln 
GDP” and “Free Trade Agreement” are not statistically significant. Moreover, the variable “ln 
GDP²” is only significant at a 10% level.  
As in the previous regression, the variables “Health spending”, “Port container”, “ln 
distance”, “ln distance²” are statistically significant at 5% level. The command margin was 
performed to evaluate the marginal effect of the distance and the GDP of the country j on 
the dependent variable.  
 
Table 10: Partial effects of “ln GDP” and “ln distance” on the dependent variable 
  dy/dx P>z 
Ln GDP (dollars) .6194133 0.000 
Ln distance (kms) -.3683497 0.000 
 
Table 10 indicates that the effect of the logarithm of GDP on the dependent variable is 
statistically significant at 0.1% level. The coefficient reveals that the relation between the 
GDP of the receiving country and the EU exports of pharmaceutical products measured in 
dollars is positive, as we expected. The result doesn’t differ from the previous regression. 
Indeed, a 1% increase in the GDP of the receiving country is expected to increase the EU 
exports of pharmaceuticals towards this country by 0.62%. The effect of the natural 
logarithm of distance on the EU exports of pharmaceuticals is also statistically significant 
at 1% level. The negative sign of the coefficient indicates that the relation between those 
two variables is negative. Therefore, a 1% increase in the distance between the EU and its 
partner country is expected to decrease the EU exports of pharmaceuticals by 0.37 %.  
 
5.4. Regression with Intellectual Property Rights  
In order to measure the impact of Intellectual Property Rights on the exports of 
Pharmaceuticals from the EU, we created a database using the Reports on Intellectual 
Property Rights Index written by the Property Right Alliance. Since these reports only 
started in 2007, the data on intellectual property was only available from 2007 until 2011.  
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Given the fact that we could only test the effect of the variable “Intellectual Property Rights” 
over a period of three years, we conducted a simple regression analysis using the method 
of Ordinary Least Square. The result is summarised in the following table:  
 
Table 11: results of the fourth regression with IPR 
 
Variables Model 4  
ln GDP (dollars) 0.642*** (0.00)    
Free Trade Agreement -0.0287    (0.81)   
Ln distance (kms) -0.610*** (0.00)   
Tuberculosis 0.0000646    (0.70)    
Landlocked -0.138    (0.62)    
Health spending 0.100*** (0.00)    
Port container 0.434*** (0.00)    
Intellectual Property Rights 0.141*** (0.00) 
Constant 7.061*** (0.00)    
Observations 161  
 
As we can see from Table 11, the variable “Intellectual Property Right (IPR)” has a 
statistically significant impact on the EU exports of pharmaceuticals at 1% level. This 
means that a one unit increase in the rating of a country on Intellectual Property Right is 
expected to increase the EU exports of pharmaceuticals by 14.1% holding other factors 
constant.  
5.5. Discussion of the results  
The first regression of our model indicates that the variables “Healthspending”, the 
logarithm of the GDP, the dummy variable “landlocked” have a statistically significant 
impact on the EU exports of pharmaceuticals at 5% level. The variable “Portcontainer” was 
also statistically significant at 10% level. However, since this regression didn’t pass the test 
of functional form misspecification, we added the square of the variable “ln GDP” and the 
square of “ln distance” into our initial equation. We also robustified our model in order to 
avoid the problem of heteroskedasticity detected by the Breusch Pagan test.  
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Table 12: Summary of the results of the different regressions 
Variables  Model 1  Model 2  Model 3  Model 4  
ln GDP (dollars) 0.620*** (0.00) -1.129* (0.03) -1.129 (0.21) 0.642*** (0.00)   
FTA 0.0880 (0.12) 0.122* (0.04) 0.122 (0.10) -0.0287    (0.81)   
Ln distance (km) -0.320 (0.13) -12.42*** (0.00) -12.42*** (0.00) -0.610*** (0.00)   
Tuberculosis -0.000126 (0.82) -0.00104 (0.20) -0.00104 (0.46) 0.0000646    (0.70)   
Landlocked -1.086* (0.04) 0.526 (0.31) 0.526 (0.40) -0.138    (0.62)    
Health spending 0.0609*** (0.00) 0.0510*** (0.00) 0.0510* (0.01) 0.100*** (0.00)    
Port container 0.943 (0.07) 2.812*** (0.00) 2.812*** (0.00) 0.434*** (0.00)    
ln GDP² (dollars)   0.0344*** (0.00) 0.0344 (0.06)                  
ln distance² kms)   0.711*** (0.00) 0.711*** (0.00)                  
IPR       0.141*** (0.00) 
Observations 496  496  496  161  
 
The second regression shows that all explanatory variables of this model are statistically 
significant at 5% level except the variables “tuberculosis” and “landlocked”. These results 
are similar to a certain extent to the one obtained by Per Adolfsson, Mats Wilkman and 
Anne Boring. Indeed, in their respective research, those authors showed that the Swedish 
and USA exports of pharmaceuticals depend positively on the economic size of the 
receiving country, and negatively on the distance between the country i and j. Contrary to 
Per Adolfsson’s results concerning the case of Sweden, this paper shows that the exports 
of EU pharmaceutical products are not influenced by access to the sea of the partner 
country.  
 
However, the presence of a major container port in the receiving country has a significant 
positive effect on the EU exports of pharmaceuticals towards those countries.  This 
conclusion is similar to the one reached by Anne Boring. Indeed, she showed that countries 
with big container ports are more likely to import pharmaceutical products from the USA. 
However, contrary to this researcher, we found that the variable “tuberculosis” did not have 
a statistically significant impact on the EU exports of pharmaceuticals even at 10% level 
whereas the total health expenditure as a percentage of GDP had a very strong positive 
effect on the dependent variable. These results can be explained by the different research 
designs of our respective researches.  
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While Anne Boring’s research focuses on the USA trade with emerging countries, this article 
examines the determinants of EU exports towards the rest of the world. This could explain 
why the variable “Tuberculosis” is statistically significant in her research and not in this 
one.  However, the significance of the variable “healthspending” in this article suggests that 
the bigger the size of the health sector of the partner country, the more the EU will have 
opportunities to export to those countries.  
 
A third regression was run to control for an eventual problem of correlation between the 
observations for each country over several years.  The result of this regression does not 
differ so much from the previous one. The biggest difference between the second and third 
regression lies in the fact that the variable Free Trade Agreement is not statistically 
significant anymore.  
 
Finally, the fourth regression reveals the strong positive effect of the protection of 
Intellectual Property Rights on the EU exports of pharmaceuticals. This result strongly 
differs from the one obtained by Anne Boring in 2010 for the case of the USA trade of 
pharmaceuticals where the dummy variables used as a proxy for Intellectual Property 
Protection did not appear to have a statistically significant impact on the dependent 
variable. The last regression performed confirms the statistical significance at 1% level of 
the GDP of the receiving country, the distance, the presence of a major port container and 
the level of health spending in the receiving country on the EU exports of pharmaceuticals. 
However, the variable Free Trade Agreement does not appear to be statistically significant 
even at 10% level. 
 
Overall, one can therefore argue that the different regressions performed confirm our main 
hypotheses. The protection of Intellectual Property, the GDP of the partner country, the 
importance of the health sector of the receiving country and the presence of a major port 
container in the country j have a positive impact on the EU exports of pharmaceuticals 
overseas. On the contrary, as we expected, the transport costs measured by the distance 
between the EU and the receiving country have a negative effect on the extra EU-25 exports 
of pharmaceuticals. It is difficult, however, to draw any definitive conclusions regarding the 
impact of Free Trade Agreements on the EU exports of pharmaceuticals since the last 
regressions of this econometric analysis yield different results.  
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6. Conclusions 
 
The EU pharmaceutical industry is an important source of growth and competitiveness for 
the European Economy. However, despite the importance of this sector for the future of the 
European Union, few academics have analyzed the European pharmaceutical industry from 
a trade-related perceptive. Most of the research on the European pharmaceutical industry 
generally focuses on its impact on the health sector or on the rules to maintain competition 
in the industry. This lack of research on the EU exports of pharmaceuticals is all the more 
surprising in a context of economic crisis where trade has a major role to play to boost EU 
competitiveness and growth. The aim of this paper was to fill this literature gap by 
enhancing our knowledge of the drivers and obstacles to the extra-EU exports of 
pharmaceuticals.  
 
The first section of this paper summarises the main findings of some official reports 
regarding the main barriers for the EU exports of pharmaceuticals. This literature review 
sheds light on the importance of tariffs and non-tariff barriers as well as on the level of 
intellectual Property Rights on the EU exports of pharmaceuticals. This paper seeks to 
complete this qualitative analysis by providing an econometric assessment of the main 
determinants of the EU exports of pharmaceuticals. Based on the Gravity model of Trade, 
this paper formulated various hypotheses concerning the determinants of the EU exports of 
pharmaceuticals. 
 
This research has revealed that several variables have a significant impact on the EU 
exports of pharmaceuticals. We found that the economic size of the partner country has a 
positive effect on the exports of pharmaceuticals, while the distance between the EU and 
the importing countries has a negative impact on the trade of pharmaceuticals. This paper 
also shows the importance of the quality of infrastructure on the trade of pharmaceuticals. 
Indeed, the different regressions highlight that countries with large container ports tend to 
import more pharmaceutical products from the EU.  The EU exports of pharmaceuticals 
were also influenced by the size of the healthcare sector of the partner country. Thus, the 
EU is likely to export more pharmaceutical products to countries that have a higher level of 
healthcare expenditure as a percentage of GDP.  Finally, this paper shows that the level of 
Intellectual Property Rights of the receiving country has a positive effect on the EU exports 
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of pharmaceuticals. Indeed, the higher the protection of Intellectual Property in one country, 
the more the EU will be able to export pharmaceutical products towards this state. 
However, access to the sea of the receiving countries did not have a statistically significant 
impact on the dependent variable. Moreover, it was difficult to draw any definitive 
conclusions regarding the impact of Free Trade Agreements on the EU exports of 
pharmaceuticals since our regressions yield different results. Based on the gravity model of 
trade, this paper sheds light on the key drivers to the EU exports of pharmaceuticals. 
However, further analysis could be carried out to in the future to quantify the impact of tariff 
and non-tariff barriers on the exports of pharmaceuticals. It could also be interesting to 
adopt a comparative approach to examine to what extent the factors driving the exports of 
pharmaceuticals are the same in different countries.  
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Appendix 
 
List of countries included in the sample  
 
 
Cameroon 
Pakistan 
Colombia 
Albania 
Panama 
Benin 
Georgia 
Congo 
Kenya 
Gabon 
Japan 
Indonesia 
South Korea 
Malaysia 
Philippine 
Thailand 
China 
Canada 
United states 
Brazil 
Chile 
Colombia 
Ecuador 
Peru 
Venezuela 
Bolivia 
Paraguay 
Uruguay 
India 
Ethiopia 
Qatar 
 
 
 
Russia 
Switzerland 
Australia 
Ukraine 
Algeria 
Saudi Arabia 
South Africa 
Norway 
United Arab 
Emirates 
Croatia 
Vietnam 
Israel 
Mexico 
Kazakhstan 
Egypt 
Morocco 
Jordan 
Côte d'Ivoire 
Lebanon 
Nigeria 
Belarus 
Senegal 
Bosnia and 
Herzegovina 
Singapore 
Iraq 
New Zealand 
Uzbekistan 
Kuwait 
Ghana 
Angola 
Sudan 
